Good info From Yahoo; very interesting! Mass obduction

New Post Public Reply Private Reply Replies (2) Message Board
reallypeople?
751
Good info

From Yahoo; very interesting!

Mass obduction in Hamburg hospital
What causes covid 19 deaths
Hamburg forensic pathologists performed autopsies on more than 600 Covid-19 deaths to understand the course and cause of death. They found out what people with severe courses die of and what can prevent death in some cases.
Most Covid 19 patients with a severe course die from the viral infection due to pre-existing conditions and because of their advanced age. This is the result of an evaluation by the Institute of Forensic Medicine at the University Medical Center Hamburg-Eppendorf (UKE). The physicians performed 735 autopsies last year. Of these, 618 died from Covid-19. In seven percent, however, another cause was responsible for the death, they said.

Overall, 88 percent of those who died from Covid-19 had at least three to four pre-existing conditions, he said, and the vast majority of all deaths were older than 76. Some deaths with the new Covid-19 mutations have also been autopsied, UKE scientists said. However, the causes of death were the same as with the conventional virus variant.

But the forensic scientists also had some good news: the number of Covid-19 deaths from pulmonary embolism has dropped noticeably. "Among the first hundred deaths in the spring of last year, more than half still died from pulmonary embolisms," said forensic pathologist Benjamin Ondruschka when asked by SPIEGEL. In the meantime, he said, the number has declined noticeably.

The chances of survival for seriously ill Covid 19 patients could be increased by anticoagulants. This was also confirmed by the autopsy of the more than 600 cases, Ondruschka said. The anticoagulants - or blood thinners - reduce thrombosis and pulmonary embolism. As the study of the deceased showed, life was prolonged by the blood thinners, yet the patients could not always be saved.

Already in May, researchers at the UKE had warned that blood clotting often becomes extremely unbalanced due to Sars-CoV-2. In many Covid-19 patients, the blood clots, they said at the time.

The German Society for Thrombosis and Hemostasis Research also recommended at the time that every hospitalized patient be treated with the drug heparin in high doses, unless there was something to the contrary.

"The anticoagulants help, but cannot prevent fatal pulmonary embolisms in every case," said study author Ondruschka. Nevertheless, he said, physicians have had a "learning curve" since the first wave a year ago. "We have reduced the absolute number of thromboses and prolonged the phase of survival for the final deceased," the forensic physician said at the presentation of the study in Hamburg.

Causes of death: Age, pre-existing conditions and obesity
Most corona patients with severe courses die of multiple organ failure or sepsis in addition to pulmonary emboli.

Often, these causes of death are favored by a number of pre-existing conditions, which are particularly prevalent in people of advanced age, the UKE scientists said. People with severe courses usually suffered from high blood pressure, renal insufficiency, diabetes, tumors or chronic obstructive pulmonary disease (COPD). Only one percent of those who died had no previous illness - here, more detailed research is needed into the causes.

An unhealthy lifestyle is often an aggravating factor: 20 percent of those who died were morbidly overweight, he said. "Obesity is a decisive factor in severe courses," Ondruschka said.

The youngest Corona deceased autopsied by medical examiners was 29 years old, he said, and the oldest deceased was 100. Seven people died as a result of the infection before reaching the age of 50. The men who died were statistically slightly younger than the women, and more men died than women. Children or adolescents were not among the deaths studied.

Only one effective drug
Despite intensive research, there are still too few effective drugs against covid-19, says Stefan Kluge, head of the hospital's intensive care clinic. "Dexamethasone is the only drug that has been shown to reduce mortality," Kluge says. With remdesivir, on the other hand, high hopes would have been disappointed. "Large studies have shown that remdesivir has little effect on severely ill patients," Kluge said.

Currently, 400 drugs are being studied worldwide, but there are also extremely many setbacks, he said. "We know, for example, that vitamin D does not protect against severe courses, despite all the announcements," Kluge said.
sug/dpa

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

OSL Unveils Instant Redemption for USDGO Plus SP

Updated Category News Views 148

OSL's New Move: Instant Redemption on the Table Alright, let's chew over OSL's latest gambit—you know, those folks (HKEX: 863) who are knee-deep in the digital currency swamp. They've launched this "Instant Redemption" feature for these fancy real-world asset products, and USDGO Plus SP is right there at the forefront. Getting the Fine Print Straight Now, not just...

Continue Reading
PG&E, Edison Push Liability Cap Amid Firestorm

Updated Category News Views 152

The Thanksgiving Playbook Nobody Wanted Sacramento's corridors are buzzing with electric tension. And why? It's not some trivial turkey drama but a simmering scandal over two utility giants trying to sneak a liability cap into law faster than you can ask for a second slice of pumpkin pie. PG&E and Edison have a little secret—a covert strategy to limit shareholder...

Continue Reading
Montefiore Einstein Takes On Breast Cancer's Hidden Battle

Updated Category News Views 49

Call me old-fashioned, but when cancer whispers in the shadows even after it's supposedly signed off the death certificate, you're dealing with one heck of a slippery adversary. That's where Montefiore Einstein Comprehensive Cancer Center comes in, armed with ten million greenbacks from the National Cancer Institute, primed to rattle the labyrinth of breast cancer...

Continue Reading
Tulsa Hosts Gradient's Global Tech and Investment Event

Updated Category News Views 89

Tulsa's New Spotlight: Gradient's CHROMA Event Well, look at Tulsa, becoming the center of the tech and enterprise universe for a day. Gradient is throwing open the doors for its second annual CHROMA event on September 24, 2026. You might scratch your head and say, ‘Tulsa? Really?’ But hear me out—this isn’t just a local shindig. We're talking about a one-day...

Continue Reading
Minghui and ASKA Seal Major Licensing Deal for MHB018A

Updated Category News Views 164

Breaking New Ground in Thyroid Eye Disease Treatment If there's one thing that keeps the biopharma world on its toes, it's the relentless pursuit of groundbreaking treatments. And folks, let me tell you, the latest tie-up between Minghui Pharmaceutical and ASKA Pharmaceutical has struck a chord. This union with MHB018A at its core might be one of those watershed moments...

Continue Reading
Cloud Software Group Amends $2B Cash Tender Offer

Updated Category News Views 89

Cloud Software Group is stirring the pot with an amendment that'll have bondholders looking twice at their portfolios. On November 3, 2026, the company announced a tweak to its cash tender offer, bumping up the payment for its 9.00% Senior Secured Second Lien Notes due 2029. The payout now jumps from $1,017.50 to $1,022.50 for each $1,000 of principal. If you're holding...

Continue Reading
Japan's RWE Market Transformation: TXP's Insightful Whitepaper

Updated Category News Views 55

Unraveling the Real-World Evidence Landscape in Japan The folks at TXP Medical just dropped a bombshell of a whitepaper that'll have Medical Affairs departments buzzing. Imagine waking up to a market that's exploding by over 500% in just a decade—yeah, I'm talking about the EMR-derived data market in Japan. These guys are saying it's gonna shoot from ¥3.9 billion in...

Continue Reading
Hyundai Pushes Hydrogen Boundaries at 2026 Expo

Updated Category News Views 105

A Bold Step Into the Hydrogen Era Hyundai's really stepping it up at the World Hydrogen Expo 2026. They're not just dipping their toes in the hydrogen pool—they're diving in headfirst, showing off integrated hydrogen solutions that are nothing short of ambitious. Hydrogen Production That's a Real Game Changer This ain't just talk. Hyundai's showcasing modular PEM...

Continue Reading
Qapture's Institutional Stablecoin Venture Unveiled

Updated Category News Views 69

Stablecoin Strategy Meets Institutional Investment Here's a fresh one from the digital asset universe. We're talking about Qapture Investments' bold move to launch an institutional-grade stablecoin yield strategy. This ain't your average kitchen table crypto chat—it's the Qapture Safe Haven Vault (QHVN-USD), tailored for those looking to get a better return on their...

Continue Reading
Hormel Foods Sets Stage for Q4 Earnings Call in December

Updated Category News Views 124

Hormel Foods Prepares for Earnings Spotlight In a world where market instability feels like the only constant, Hormel Foods Corporation (NYSE:HRL) is setting up one of those must-watch moments. You've got DECEMBER 3rd circled on your cal, right? If not, you're about to miss a curtain raiser that could send ripples across portfolios. Setting the Stage: December's Big...

Continue Reading

Top 5 Most Recently Viewed Articles

KAYALI Unveils Irresistible Oudgasm Fragrances for All

Updated Category News Views 370

KAYALI Introduces Exciting New Fragrances KAYALI, the extraordinary fragrance house created by Mona Kattan, has once again captivated the world by expanding its popular Oudgasm Collection. The new scents include Oudgasm Chocolate Oud | 11 Eau de Parfum Intense and Oudgasm Milky Musk Oud | 30 Eau de Parfum Intense. These additions offer an innovative twist on oud, one of...

Continue Reading
Ingersoll Rand Announces Earnings Release and Call Details

Updated Category News Views 68

Ingersoll Rand Inc. (NYSE: IR) was gearing up to drop its third-quarter earnings in October 2024, and you know how these releases can shake the tree. With the market closing on a Thursday, traders were already calculating their bets ahead of this release—a classic pre-weekend play where anything could happen. What Traders Anticipated from Ingersoll Rand's Q3 Earnings...

Continue Reading
AppWork Secures Significant Funding to Enhance Operations

Updated Category News Views 218

AppWork Secures $13 Million in Series A Funding Investment will accelerate product development and customer success as AppWork scales its industry-leading platform AppWork, a fast-growing software platform designed to optimize maintenance operations for multifamily property management teams, has successfully secured $13 million in Series A funding. The investment was led...

Continue Reading
Mecho's Launch of EcoGlass Blackout Enhances Sustainability Efforts

Updated Category News Views 195

Mecho Enhances Sustainability with EcoGlass Blackout Mecho, a renowned leader in commercial shading solutions, has recently accomplished a significant sustainability milestone by introducing Environmental Product Declarations (EPDs) for its motorized shade systems, alongside its groundbreaking product EcoGlass Blackout. This innovative blackout fabric is the first of its...

Continue Reading
Vivoryon Therapeutics N.V. Prepares for Q1 2025 Financial Update

Updated Category News Views 318

Vivoryon Therapeutics N.V. Announces Q1 2025 Financial Results Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) is gearing up to unveil its financial results for the first quarter of 2025. This announcement is pivotal as it not only reflects the company's financial health but also signals its ongoing commitment to advancing treatments for inflammatory...

Continue Reading